HC Wainwright Comments on Oculis’ Q3 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS) – Research analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for Oculis in a research report issued on Monday, August 10th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.48) per share for the quarter, down from their previous estimate of ($0.47). HC Wainwright currently has a “Buy” rating and a $26.00 target price on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.15) per share. HC Wainwright also issued estimates for Oculis’ Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.75) EPS, Q1 2027 earnings at ($0.48) EPS, Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.48) EPS, Q4 2027 earnings at ($0.48) EPS and FY2027 earnings at ($1.94) EPS.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.20) EPS for the quarter. The firm had revenue of $0.38 million for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%.

Other research analysts also recently issued reports about the company. Robert W. Baird lowered their target price on Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a research report on Monday, June 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Friday, July 17th. Wall Street Zen raised shares of Oculis from a “strong sell” rating to a “sell” rating in a research note on Saturday. Stifel Nicolaus lowered their price objective on shares of Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Finally, Guggenheim dropped their price objective on shares of Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.33.

Oculis Stock Performance

NASDAQ:OCS opened at $12.75 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.35 and a quick ratio of 8.35. Oculis has a 1 year low of $10.52 and a 1 year high of $34.47. The stock’s 50 day simple moving average is $12.14 and its two-hundred day simple moving average is $22.10. The company has a market cap of $739.25 million, a price-to-earnings ratio of -7.33 and a beta of 0.51.

Hedge Funds Weigh In On Oculis

A number of institutional investors and hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. increased its position in shares of Oculis by 100.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares during the last quarter. Koshinski Asset Management Inc. bought a new stake in Oculis in the first quarter worth $238,000. Millennium Management LLC bought a new stake in Oculis in the fourth quarter worth $312,000. Himension Capital Singapore PTE. LTD. purchased a new position in Oculis during the first quarter worth $503,000. Finally, Marshall Wace LLP bought a new position in Oculis during the second quarter valued at $393,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.